(Q37978815)

26 August 2017

title

Management of myeloproliferative neoplasms: from academic guidelines to clinical practice (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

Giovanni Barosi

1

1 reference

26 August 2017

Letizia Lupo

series ordinal

2

1 reference

26 August 2017

Vittorio Rosti

series ordinal

3

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Current hematologic malignancy reports

26 August 2017

published in

1 reference

26 August 2017

volume

7

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

50-56

1 reference

MPN-associated myelofibrosis (MPN-MF).

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

New mutations and pathogenesis of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Guideline for investigation and management of adults and children presenting with a thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

No treatment for low-risk thrombocythaemia: results from a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

A phase-2 trial of low-dose pomalidomide in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

5-Azacitidine has limited therapeutic activity in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0109-7

Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

21 January 2018

1 reference

12 December 2020

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

12 December 2020

Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea

1 reference

12 December 2020

Phase1/-2 study of Pomalidomide in myelofibrosis

1 reference

12 December 2020

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

12 December 2020

Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

12 December 2020

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

1 reference

12 December 2020

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

1 reference

12 December 2020

Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

1 reference

12 December 2020

Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia

1 reference

12 December 2020

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

12 December 2020

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

1 reference

12 December 2020

Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

1 reference

12 December 2020

10.1007/S11899-011-0109-7

Identifiers

DOI

1 reference

26 August 2017

1 reference